演題抄録

一般口演

開催概要
開催回
第56回・2018年・横浜
 

当院での切除不能進行・再発胃癌に対するramucirumab50例の効果

演題番号 : O28-1

[筆頭演者]
演者)片柳 創:1,3 
[共同演者]
笠原 健大:1,3、桒原 寛:1,3、久田 将之:1,3、小金澤 樹:1、横塚 慧:1、田渕 悟:1、千葉 斉一:1、土田 明彦:3、中村 郁夫:2、河地 茂行:1

1:東京医科大学八王子医療センター・消化器外科・移植外科、2:東京医科大学・八王子医療センター・消化器内科、3:東京医科大学病院・消化器外科・小児外科

 

Introduction : As a result of the RAINBOW study, it was found that the OS was extended for Ramucirumab (Ram)+paclitaxel (PTX) combination therapy rather than taxane monotherapy, which was recommended as a secondary treatment for conventional unresectable and recurrent advanced gastric cancer. At the same time, as a result of the REGARD study, Ram monotherapy gained an extension of OS over BSC in the second line treatment. Perpose : We examined the effect of Ram. Patients and Methods : 50 patients used in our hospital since June 2015. Male 38, 12 females, median age at onset was 69 years old. Ram/PTX combined use (RP group) 45, Ram alone (R group) 5 cases. Treatment results and adverse events of RP group and R group were examined. Results : The median observation period after Ramucirumab started was 269 days. The median effective value was 5 courses in the RP group and 157 days in the PFS.RP group was 1st line: 4, 2nd line: 36, 3rd line: 4 cases, 4th line: 1 case, R group was 2nd line: 2 cases, 3rd, 4th and 5th line were each one case. case. Response rate of RP group was 28% and DCR was 72%. Hematotoxicity of Gr.3≦ was 36% in leukopenia, 43% in neutropenia, 11% in thrombocytopenia and 4% in FN. Non - hematologic toxicity was associated with Ram in 1 case of gastric perforation G4, but all others were Gr.2≧. PTX related Gr.3≦ had peripheral neuropathy 4%, fatigue 16%, hyperbilirubinemia 4%, appetite reduction 8%. Dose intensity was median Ram 100%, PTX 76%. Conclusion : Ramucirumab is considered to be an agent that can manage adverse events well and can be expected sufficiently in clinical practice.

キーワード

臓器別:胃・十二指腸

手法別:化学療法

前へ戻る